| 39.1618 0.012 (0.03%) | 12-05 10:03 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 48.16 | 1-year : | 56.26 |
| Resists | First : | 41.24 | Second : | 48.16 |
| Pivot price | 39.34 |
|||
| Supports | First : | 38.01 | Second : | 36.02 |
| MAs | MA(5) : | 39.45 |
MA(20) : | 39.27 |
| MA(100) : | 37.03 |
MA(250) : | 0 | |
| MACD | MACD : | 0.4 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 62 |
D(3) : | 67.5 |
| RSI | RSI(14): 52.4 |
|||
| 52-week | High : | 41.24 | Low : | 25.39 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RPRX ] has closed above bottom band by 37.5%. Bollinger Bands are 23.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 39.69 - 39.88 | 39.88 - 40.07 |
| Low: | 38.41 - 38.65 | 38.65 - 38.89 |
| Close: | 38.7 - 39.09 | 39.09 - 39.47 |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Fri, 05 Dec 2025
Royalty Pharma PLC $RPRX Shares Acquired by Schroder Investment Management Group - MarketBeat
Thu, 04 Dec 2025
Royalty Pharma (NASDAQ:RPRX) CFO Sells $2,774,234.34 in Stock - MarketBeat
Thu, 04 Dec 2025
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells $931,686.69 in Stock - MarketBeat
Thu, 04 Dec 2025
Denali, Royalty Pharma Ink $275Mln Royalty Financing Agreement - Nasdaq
Thu, 04 Dec 2025
Royalty Pharma (Nasdaq: RPRX) in $275M Denali royalty deal as FDA reviews tividenofusp - Stock Titan
Thu, 04 Dec 2025
OMERS ADMINISTRATION Corp Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 427 (M) |
| Shares Float | 375 (M) |
| Held by Insiders | 8.8 (%) |
| Held by Institutions | 81.6 (%) |
| Shares Short | 24,030 (K) |
| Shares Short P.Month | 13,580 (K) |
| EPS | 1.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.94 |
| Profit Margin | 32.5 % |
| Operating Margin | 70.2 % |
| Return on Assets (ttm) | 5.2 % |
| Return on Equity (ttm) | 13.1 % |
| Qtrly Rev. Growth | 7.9 % |
| Gross Profit (p.s.) | 5.85 |
| Sales Per Share | 5.5 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -45.3 % |
| Operating Cash Flow | 2,410 (M) |
| Levered Free Cash Flow | -591 (M) |
| PE Ratio | 22.35 |
| PEG Ratio | 0 |
| Price to Book value | 2.61 |
| Price to Sales | 7.11 |
| Price to Cash Flow | 6.93 |
| Dividend | 0.21 |
| Forward Dividend | 0 |
| Dividend Yield | 0.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|